Nico van Zandwijk
Overview
Explore the profile of Nico van Zandwijk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
125
Citations
3850
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Zandwijk N, Frank A, Reid G, Roe O, Amos C
Lung Cancer
. 2024 Jul;
194:107861.
PMID: 39003938
Asbestos, a group of class I (WHO) carcinogenic fibers, is the main cause of mesothelioma. Asbestos inhalation also increases the risk to develop other solid tumours with lung cancer as...
2.
Shrestha P, Kao S, Cheung V, Cooper W, van Zandwijk N, Rasko J, et al.
Mol Oncol
. 2024 Jul;
PMID: 38956984
Small cell lung cancer (SCLC) is a highly aggressive cancer with a dismal 5-year survival of < 7%, despite the addition of immunotherapy to first-line chemotherapy. Specific tumor biomarkers, such...
3.
Frank A, van Zandwijk N
Lung Cancer
. 2024 Jun;
193:107828.
PMID: 38838517
All six fiber types called asbestos can cause all the diseases related to exposure, including lung cancer. Known to the ancients, the modern history of asbestos hazards started in the...
4.
Ke H, Kao S, van Zandwijk N, Rasko J, Yeo D
Lung Cancer
. 2024 May;
192:107829.
PMID: 38810528
Asbestos-Related Lung Cancer (ARLC) presents ongoing diagnostic challenges despite improved imaging technologies. The long latency period, coupled with limited access to occupational and environmental data along with the confounding effects...
5.
6.
van Zandwijk N, Marshall H, Fong K
Respirology
. 2023 Apr;
28(6):511-512.
PMID: 37105901
No abstract available.
7.
van Zandwijk N, Amos C, Roe O, Reid G, Klebe S
JTO Clin Res Rep
. 2023 Apr;
4(4):100500.
PMID: 37077198
No abstract available.
8.
Sagnella S, White A, Yeo D, Saxena P, van Zandwijk N, Rasko J
Pharmacol Res
. 2022 Jun;
182:106329.
PMID: 35772645
Cellular therapies utilizing T cells expressing chimeric antigen receptors (CARs) have garnered significant interest due to their clinical success in hematological malignancies. Unfortunately, this success has not been replicated in...
9.
Williams M, Cheng Y, Phimmachanh M, Winata P, van Zandwijk N, Reid G
Cancer Drug Resist
. 2022 May;
2(4):1193-1206.
PMID: 35582270
Aberrant microRNA expression is a common event in cancer drug resistance, however its involvement in malignant pleural mesothelioma (MPM) drug resistance is largely unexplored. We aimed to investigate the contribution...
10.
Hyland R, Chrzanowska A, Hannaford-Turner K, Davis A, Ke H, Bradbury L, et al.
Asia Pac J Clin Oncol
. 2022 Jan;
18(5):e448-e455.
PMID: 35100476
Background And Objectives: Due to difficulties in identifying sufficient-sized cohorts there remains uncertainty about prognostic and clinical differences that may be unique to asbestos-related lung cancer (ARLC). In this study,...